These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11316866)

  • 61. Dietary potassium and magnesium supplementation in cyclosporine-induced hypertension and nephrotoxicity.
    Pere AK; Lindgren L; Tuomainen P; Krogerus L; Rauhala P; Laakso J; Karppanen H; Vapaatalo H; Ahonen J; Mervaala EM
    Kidney Int; 2000 Dec; 58(6):2462-72. PubMed ID: 11115079
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis.
    Martin DF; DeBarge LR; Nussenblatt RB; Chan CC; Roberge FG
    J Immunol; 1995 Jan; 154(2):922-7. PubMed ID: 7814893
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Conversion to sirolimus in kidney transplant recipients: a single-center study.
    Ganji MR; Hakemi MS; Esfehani F; Alatab S; Naderi GH
    Iran J Kidney Dis; 2013 Jul; 7(4):309-15. PubMed ID: 23880809
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pioglitazone limits cyclosporine nephrotoxicity in rats.
    Pereira MG; Câmara NO; Campaholle G; Cenedeze MA; de Paula Antunes Teixeira V; dos Reis MA; Pacheco-Silva A
    Int Immunopharmacol; 2006 Dec; 6(13-14):1943-51. PubMed ID: 17161347
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
    Bara C; Dengler T; Hack MA; Ladenburger S; Lehmkuhl HB
    Transplant Proc; 2013; 45(6):2387-92. PubMed ID: 23953553
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
    Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
    Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Addition of induction therapy offsets the hazard of marked calcineurin minimization among renal transplant recipients treated with sirolimus.
    Kahan BD; Benavides C; Schoenberg L; Podbielski J; Green C
    Clin Nephrol; 2010 May; 73(5):344-53. PubMed ID: 20420794
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure.
    Lehmkuhl H; Ross H; Eisen H; Valantine H
    Transplant Proc; 2005 Dec; 37(10):4145-9. PubMed ID: 16387066
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice.
    Matsumoto Y; Hof A; Baumlin Y; Hof RP
    Transplantation; 2003 Oct; 76(8):1166-70. PubMed ID: 14578747
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers.
    Zaltzman JS
    Transplantation; 2010 Dec; 90(11):1185-91. PubMed ID: 21166111
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Correlation between pretransplantation test dose cyclosporine pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant recipients.
    Kaplan B; Meier-Kriesche HU; Napoli KL; Kahan BD
    Ther Drug Monit; 1999 Feb; 21(1):44-9. PubMed ID: 10051053
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Quercetin, a bioflavonoid, protects against oxidative stress-related renal dysfunction by cyclosporine in rats.
    Satyanarayana PS; Singh D; Chopra K
    Methods Find Exp Clin Pharmacol; 2001 May; 23(4):175-81. PubMed ID: 11676225
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism.
    Gottschalk S; Cummins CL; Leibfritz D; Christians U; Benet LZ; Serkova NJ
    Neurotoxicology; 2011 Jan; 32(1):50-7. PubMed ID: 21075140
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.
    Johnson RW; Kreis H; Oberbauer R; Brattström C; Claesson K; Eris J
    Transplantation; 2001 Sep; 72(5):777-86. PubMed ID: 11571437
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prevention of cyclosporin nephrotoxicity with a platelet-activating factor (PAF) antagonist.
    Bagnis C; Deray G; Dubois M; Pirotzky E; Jacquiaud C; Baghos W; Aupetit B; Braquet P; Jacobs C
    Nephrol Dial Transplant; 1996 Mar; 11(3):507-13. PubMed ID: 8671822
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA;
    Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Angiotensin converting enzyme inhibition and chronic cyclosporine-induced renal dysfunction in type 1 diabetes.
    Hannedouche TP; Natov S; Boitard C; Lacour B; Grünfeld JP
    Nephrol Dial Transplant; 1996 Apr; 11(4):673-8. PubMed ID: 8671857
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Serum and renal tissue markers of nephropathy in rats under immunosuppressive therapy: cyclosporine versus sirolimus.
    Sereno J; Parada B; Rodrigues-Santos P; Lopes PC; Carvalho E; Vala H; Teixeira-Lemos E; Alves R; Figueiredo A; Mota A; Teixeira F; Reis F
    Transplant Proc; 2013 Apr; 45(3):1149-56. PubMed ID: 23622648
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits.
    Dias VC; Madsen KL; Mulder KE; Keelan M; Yatscoff RW; Thomson AB
    Dig Dis Sci; 1998 Oct; 43(10):2227-36. PubMed ID: 9790458
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients.
    Kelly PA; Napoli K; Kahan BD
    Biopharm Drug Dispos; 1999 Jul; 20(5):249-53. PubMed ID: 10594869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.